Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments
[18F]FET PET identifies a higher number of patients with measurable disease compared to conventional MRI in newly diagnosed glioblastoma. PET-based assessment may serve as a novel baseline parameter for evaluating residual tumor burden and improving patient stratification in glioblastoma studies. Further validation in prospective trials is warranted.
Authors
- Stephan Schönecker (ORCID: https://orcid.org/0000-0003-0359-8960)
- Robert Forbrig (ORCID: https://orcid.org/0000-0002-1054-1463)
- Enio Barci (ORCID: https://orcid.org/0009-0000-6747-2684)
- Patrick N. Harter (ORCID: https://orcid.org/0000-0001-5530-6910)
- Lucas Wiegand (ORCID: https://orcid.org/0000-0002-4813-2278)
- Louisa von Baumgarten (ORCID: https://orcid.org/0000-0002-6634-0927)
- Christian Schichor (ORCID: https://orcid.org/0000-0001-6684-3578)
- Nathalie L. Albert (ORCID: https://orcid.org/0000-0003-0953-7624)
- Matthias Preusser (ORCID: https://orcid.org/0000-0003-3541-2315)
- Lena Kaiser (ORCID: https://orcid.org/0000-0002-2084-5858)
- Niklas Thon (ORCID: https://orcid.org/0000-0003-0011-5281)
- Jonas Reis (ORCID: https://orcid.org/0000-0001-8932-2265)
- Katharina Müller (ORCID: https://orcid.org/0000-0001-7098-4744)
- Sophie C. Kunte (ORCID: https://orcid.org/0009-0003-3175-952X)
Institutions
- German Cancer Research Center (DE)
- LMU Klinikum (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Medical University of Vienna (AT)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1093/neuonc/noae208
- Citations
- 10
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.38